We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cell Surface Protein Deletion Blocks AML Growth in Mouse Model

By LabMedica International staff writers
Posted on 03 Aug 2015
Cancer researchers have found that the cell surface protein tetraspanin3 (Tspan3) is required for the development and propagation of the fast-growing and extremely difficult-to-treat blood cancer, acute myelogenous leukemia (AML).

AML is an aggressive cancer that strikes both adults and children and is frequently resistant to therapy. More...
Thus, identifying signals needed for AML propagation is a critical step toward developing new approaches for treating this disease.

Towards this end, investigators at the University of California, San Diego (USA; www.ucsd.edu) examined the role of Tspan3 by genetically engineering a line of mice to lack the gene required for production of this protein.

The investigators reported in the July 23, 2015, online edition of the journal Cell Stem Cell that Tspan3 "knockout" mice were born without overt defects. However, Tspan3 deletion impaired leukemia stem cell self-renewal and disease propagation and markedly improved survival in mouse models of AML. Additionally, Tspan3 inhibition blocked growth of AML patient samples, suggesting that Tspan3 was also important in human disease.

Results also showed that at the molecular level Tspan3 was a target of the RNA binding protein Musashi 2, which plays a key role in AML, and that the chemokine response of AML cancer cells was impaired by Tspan3 deletion.

“There has been great progress in pediatric leukemia research and treatment over the last few years,” said senior author Dr. Tannishtha Reya, professor of pharmacology at the University of California, San Diego. “But unfortunately, children with acute myeloid leukemia are often poor responders to current treatments. So identifying new approaches to target this disease remains critically important.”

“Tetraspanin3 (Tspan3), a cell surface molecule, serves as a key link for cancer cells to interact with supportive parts of the microenvironment that help them replicate and flourish,” said Dr. Reya. “We found that blocking this molecule leads to a very profound inhibition of leukemia growth. The work really focuses on trying to understand the dependence of cancer cells on the microenvironment that surrounds them. The microenvironment refers to the normal cells, molecules, and blood vessels around the cancer that may support and fuel its expansion.

Related Links:

University of California, San Diego



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.